Clinical Development of CT327, a novel treatment for childhood Atopic Dermatitis

儿童特应性皮炎新疗法 CT327 的临床开发

• 批准号: 101375
• 金额: $ 181.29万
• 依托单位: CREABILIS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101375
• 关键词: Clinical; Development; CT327; novel; treatment

The CT327 Atopic Dermatitis (AD) project aims to further develop Creabilis' novel topical treatment for AD in children. Creabilis is a clinical stage biotech company developing drugs in dermatology, with a team experienced in bringing new drugs to market. We intend to further develop CT327 in childhood AD, an area of significant and often neglected unmet medical need, demanding effective, but safer drugs. We believe CT327 will meet these needs. CT327 has a novel MoA and will treat all symptoms of AD, including the itch component of the disease that has the greatest impact on quality of life. Developed using Creabilis’ Low Systemic Exposure (LSE) technology, CT327 has a favourable safety profile in the 5 clinical studies carried out to date. TSB funding will allow Creabilis to complete a Phase 2b AD study in children that will definitively demonstrate the safety and efficacy characteristics that will allow CT327 to be positioned as a novel long-term topical treatment for childhood AD.

CT327特应性皮炎（AD）项目旨在进一步开发Creabilis针对儿童AD的新型局部治疗。Creabilis是一家临床阶段的生物技术公司，开发皮肤科药物，其团队在将新药推向市场方面经验丰富。我们打算在儿童AD中进一步开发CT327，这是一个重要且经常被忽视的未满足医疗需求的领域，需要有效但更安全的药物。我们相信CT327将满足这些需求。CT327具有新的MoA，将治疗AD的所有症状，包括对生活质量影响最大的疾病的瘙痒部分。使用Creabilis的低全身暴露（LSE）技术开发，CT327在迄今为止进行的5项临床研究中具有良好的安全性。TSB的资助将使Creabilis能够完成儿童AD的2b期研究，该研究将明确证明CT327的安全性和有效性特征，使其成为儿童AD的新型长期局部治疗药物。